Loading data for PTHS — first visit, this takes a few seconds.
Pelthos Therapeutics Inc. (PTHS)
NYSE American: PTHS
· 即時價格 · USD
21.90
-0.53 (-2.36%)
收盤價： Sep 11, 2026, 3:59 PM
股價、關鍵數字和最新消息，都在這一頁。
Pelthos Therapeutics Inc.（PTHS）股價、分析與資料
-2.36% (1D)
| 買價 | 16.02 |
| 市值 | 83.8M |
| 營收 (ttm) | 43.3M |
| 淨利（ttm） | -86.4M |
| 3.05 | |
| -28.63 | |
| n/a | |
| -3.85 | |
| P/B (ttm) | -54.21 |
| P/S (ttm) | 1.94 |
| 財報日期 | Nov 12, 2026 |
| 賣價 | 27.55 |
| 成交量 | 18,937 |
| 20 日平均成交量 | 59,773 |
| 開盤價 | 22.62 |
| 前收盤價 | 22.43 |
| 當日區間 | 21.21 - 22.88 |
| 52 週範圍 | 18.19 - 37.50 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 PTHS
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months ...
完整的公司簡介財報驚奇
Pelthos Therapeutics 已於 Aug 13, 2026 公布季度財報：
- 營收為 $15.6M 低於預期 $0, 年增 Infinity% 成長.
- 每股盈餘為 -3.79 低於預期 -0.84, 年增 29.55% 成長.
第 1 頁，共 2 頁